Results
The results of this comparative study showed that in the efficacy-evaluable tamsulosin population (n=905), statistically and clinically significant improvement (25.3%) in mean total AUA Symptom Score was observed after 4 days of treatment. Improvement in the terazosin population (n=844) was only 18.1%. The statistically significant (P<0.001) adjusted mean change in total AUA Symptom Score after four days with tamsulosin therapy was -4.8 and -3.4 with terazosin therapy.1,2
In addition, 23 of the 42 secondary endpoint score comparisons (54.7%) were statistically significant in favor of FLOMAX, whereas the other 19 endpoint scores also favored tamsulosin.1
The figure above shows that tamsulosin offers rapid alleviation of the symptoms of BPH with a greater improvement in mean change from baseline to total AUA Symptom Score in 4 days.
See safety data from Tamsulosin vs Terazosin Trial (527.17)
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
1. Narayan P, O'Leary MP, Davidai G. Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res. 2005;5:237-245.
2. Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
